| The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. M Janakiram, UA Shah, W Liu, A Zhao, MP Schoenberg, X Zang Immunological Reviews 276 (1), 26-39, 2017 | 223 | 2017 |
| GPRC5D-Targeted CAR T Cells for Myeloma S Mailankody, SM Devlin, J Landa, K Nath, C Diamonte, EJ Carstens, ... New England Journal of Medicine 387 (13), 1196-1206, 2022 | 161 | 2022 |
| Emerging immunotherapies in multiple myeloma UA Shah, S Mailankody bmj 370, 2020 | 101 | 2020 |
| Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies R Stuver, GL Shah, NS Korde, LE Roeker, AR Mato, CL Batlevi, DJ Chung, ... Cancer Cell 40 (6), 590-591, 2022 | 83 | 2022 |
| COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers M Hultcrantz, J Richter, CA Rosenbaum, D Patel, EL Smith, N Korde, ... Blood Cancer Discovery, 2020 | 80 | 2020 |
| An update on the genetics of pheochromocytoma D Karasek, U Shah, Z Frysak, C Stratakis, K Pacak Journal of human hypertension 27 (3), 141-147, 2013 | 80 | 2013 |
| North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies UA Shah, EY Chung, O Giricz, K Pradhan, K Kataoka, S Gordon-Mitchell, ... Blood, The Journal of the American Society of Hematology 132 (14), 1507-1518, 2018 | 73 | 2018 |
| Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the … O Landgren, M Hultcrantz, B Diamond, AM Lesokhin, S Mailankody, ... JAMA oncology 7 (6), 862-868, 2021 | 71 | 2021 |
| Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial B Diamond, N Korde, AM Lesokhin, EL Smith, U Shah, S Mailankody, ... The Lancet Haematology 8 (6), e422-e432, 2021 | 56 | 2021 |
| Whole-genome landscape of adult T-cell leukemia/lymphoma Y Kogure, T Kameda, J Koya, M Yoshimitsu, K Nosaka, J Yasunaga, ... Blood, The Journal of the American Society of Hematology 139 (7), 967-982, 2022 | 54 | 2022 |
| Pheochromocytoma: implications in tumorigenesis and the actual management U Shah, A Giubellino, K Pacak Minerva endocrinologica 37 (2), 141, 2012 | 51 | 2012 |
| Comparison of MALDI‐TOF mass spectrometry analysis of peripheral blood and bone marrow‐based flow cytometry for tracking measurable residual disease in patients with multiple … M Eveillard, E Rustad, M Roshal, Y Zhang, A Ciardiello, N Korde, ... British journal of haematology 189 (5), 904-907, 2020 | 48 | 2020 |
| Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy O Van Oekelen, K Nath, TH Mouhieddine, T Farzana, A Aleman, ... Blood 141 (7), 756-765, 2023 | 47 | 2023 |
| CAR T and CAR NK cells in multiple myeloma: Expanding the targets UA Shah, S Mailankody Best Practice & Research Clinical Haematology 33 (1), 101141, 2020 | 44 | 2020 |
| Accelerated single cell seeding in relapsed multiple myeloma HJ Landau, V Yellapantula, BT Diamond, EH Rustad, KH Maclachlan, ... Nature communications 11 (1), 3617, 2020 | 43 | 2020 |
| Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: a … O Landgren, M Hultcrantz, AM Lesokhin, S Mailankody, H Hassoun, ... Blood 134, 862, 2019 | 41 | 2019 |
| Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide … K Piedra, T Peterson, C Tan, J Orozco, M Hultcrantz, H Hassoun, ... British Journal of Haematology 196 (1), 105-109, 2022 | 35 | 2022 |
| Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory … S Mailankody, C Diamonte, L Fitzgerald, P Kane, X Wang, DS Sikder, ... Blood 138, 827, 2021 | 31 | 2021 |
| Epidemiology and survival trend of adult T‐cell leukemia/lymphoma in the United States UA Shah, N Shah, B Qiao, A Acuna‐Villaorduna, K Pradhan, ... Cancer 126 (3), 567-574, 2020 | 29 | 2020 |
| Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta‐analysis of randomized clinical trials A Das, S Dasgupta, Y Gong, UA Shah, MG Fradley, RK Cheng, B Roy, ... Hematological Oncology 40 (2), 233-242, 2022 | 25 | 2022 |
